Aduro Biotech’s Stephen T. Isaacs Named 2016 Visionary Leader by Berkeley Chamber of Commerce
September 26 2016 - 8:00AM
Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that Stephen T.
Isaacs, the company’s chairman, president and CEO, will receive the
Berkeley Chamber of Commerce Visionary Award. One of three
recipients for 2016, Mr. Isaacs was recognized for his commitment
to innovation and his visionary leadership within the city of
Berkeley.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/ab2a14fb-8573-416b-989e-484f04910ffb
“Steve is a consummate innovator and incredible leader,” said G.
Steven Martin, Ph.D., former dean of Biological Sciences at the
University of California in Berkeley. “He is one of few in the
industry with the foresight to begin advancing research in
immuno-oncology over a decade ago. Additionally, his visionary
leadership has forged deep ties between biotech and academia, as
well as between the city of Berkeley and countries around the
world. A prime example of this is Aduro’s research collaboration
with U.C. Berkeley through their Immunotherapeutics and Vaccine
Research Initiative (IVRI), with the aim of accelerating
breakthrough discoveries and making an impact on global health. For
his many accomplishments and admirable character, I extend my
sincerest congratulations to Steve for this well-deserved award.”
The Berkeley Chamber of Commerce created the Visionary Awards to
celebrate people with imagination and persistence to innovate in
the City of Berkeley. Long known as a city on the vanguard of
public policy and social activism, Berkeley is growing its
reputation as a place for world-leading companies. These
enterprises represent the latest generation of Berkeleyans working
to change the world. Their visions are key to the vitality of
Berkeley and the greater Bay Area.
With the unique attributes of UC Berkeley, the Berkeley Lab, and
the dynamic community, entrepreneurs are choosing Berkeley as the
place to launch their ventures. Their companies are striving to
meet the challenges of the next generation, while at the same time,
creating jobs in the city. The Chamber has partnered with the City
of Berkeley, the University of California, and the Lawrence
Berkeley National Lab to showcase these leaders.
“We created the Visionary awards to recognize people who
are truly making a difference – for our local workforce, for
the community and, especially in the case of Steve and
Aduro, for people suffering from devastating diseases,”
commented Kirsten MacDonald, co-chief executive officer of the
Berkeley Chamber of Commerce. “We applaud Steve for his persistence
in approaching the challenging field of drug development with
unique and innovative approaches, for building a thriving
biotechnology company, and for identifying revolutionary ways to
bring academia and industry together for the benefit of patients
not only locally, but also in the developing world.”
“It is a tremendous honor to be recognized by the Chamber of
Commerce for innovation in this city, which is known for its
revolutionary thinking,” said Stephen T. Isaacs, chairman,
president and chief executive officer of Aduro. “For over a
decade, we have been in Berkeley working to bring new
immunotherapies to patients to transform the treatment of cancer
and other challenging diseases. We look forward to our continued
commitment to advance immunotherapy – for the benefit of patients,
employees and the community.”
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
pancreatic, ovarian, lung and prostate cancers, mesothelioma and
glioblastoma. Aduro's STING Pathway Activator platform is designed
to activate the intracellular STING receptor, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, the potential for our technology
platforms, plans, and the potential for eventual regulatory
approval of our product candidates. In some cases, you can identify
these statements by forward-looking words such as “may,” “will,”
“continue,” “anticipate,” “intend,” “could,” “project,” “expect” or
the negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our history of net operating losses
and uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technology platforms to build a
pipeline of product candidates, our ability to obtain and maintain
regulatory approval of our product candidates, our inability to
operate in a competitive industry and compete successfully against
competitors that have greater resources than we do, our reliance on
third parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our quarterly report on Form 10-Q for
the quarter ended June 30, 2016, which is on file with
the Securities and Exchange Commission. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Angela Bitting
925 202 6211
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024